



28 November 2013

## **ASX ANNOUNCEMENT**

### **IMPEDIMED AND INSTITUT CURIE SIGN CLINICAL TRIAL SERVICE AGREEMENT**

#### **- Multi-centre, randomized, prospective, clinical trial for breast cancer related lymphoedema -**

Brisbane, Australia – **ImpediMed Limited** (ASX: IPD) (“the Company”), announces a service agreement with the Institut Curie for the first prospective, multi-centre, clinical trial utilising L-Dex<sup>®</sup> in France. Institut Curie is one of Europe’s leading oncology research centres, with state-of-the-art hospitals and a reputation for accelerating the advancement of new clinical tools for the medical community.

This five-year, randomised controlled trial will take place at five centres in France to study early detection and treatment of lymphoedema related to breast cancer. The study is designed to follow 800 women for two years with L-Dex as the primary measurement criteria. Patients will be measured before cancer treatment, and every four to six months, up to twenty-four months post-treatment.

This represents the first major trial in the field of the prevention of lymphoedema following the treatment of breast cancer in France. This study is the first step in changing clinical practice in France to one of a pre-emptive care model for lymphoedema, however its results can be expected to have a similar impact around the world.

President and CEO Richard Carreon stated, “We are pleased that Institut Curie selected L-Dex for this very important clinical trial. This marks a critical step in the expansion of L-Dex into Europe and the continued journey of making L-Dex the standard of care for all cancer patients at risk for lymphoedema.”

#### **For further information contact:**

**Richard Carreon, ImpediMed CEO**  
**Morten Vigeland, ImpediMed CFO**  
**T: +1 (760) 585-2100**

L-Dex<sup>®</sup> is a trademark of ImpediMed Limited.

#### **About Institut Curie**

Founded in 1909 on a model devised by Marie Curie and still at the cutting edge: "from fundamental research to innovative treatments", the Institut Curie has 3,000 researchers, physicians, clinicians, technicians and administrative staff. The Research Center of the Institut Curie is one of the most important in Europe and the largest in France dedicated to cancer research. It houses more than 80 joint Institut Curie - CNRS, Inserm or University research groups whose common goal is to increase knowledge and ameliorate patient management using state-of-the-art technology platforms.

#### **About ImpediMed**

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an

For personal use only

FDA clearance in the United States to aid health care professionals clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit [www.impedimed.com.au](http://www.impedimed.com.au)

For personal use only